During the past decade, Onkologische Schwerpunktpraxis Bielefeld conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 7 clinical trials were completed, i.e. on average, 70% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Bielefeld" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "BeiGene" with 2 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "University of Heidelberg Medical Center" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Bielefeld" #1 collaborator was "Breast International Group" with 3 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Austrian Breast and Colorectal Cancer Group" with 1 trials as a collaborator, "ClinAssess" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis Bielefeld" are "Breast Cancer" (6 trials), "Leukemia" (3 trials), "Multiple Myeloma" (2 trials), "Non-Small Cell Lung Cancer (NSCLC)" (2 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis Bielefeld" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis Bielefeld" are "Drug" (19 trials), "Biological" (2 trials), "Procedure" (2 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Cyclophosphamide" (3 trials), "Docetaxel" (3 trials), "Lenalidomide" (3 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (2 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis Bielefeld" are 17 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis Bielefeld". undefined are not yet recruiting, 1 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Onkologische Schwerpunktpraxis Bielefeld, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis Bielefeld, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".